(Q44280538)

English

A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia

scientific article published in April 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Astrid Gruber

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Magnus Björkholm

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Lorentz Brinch

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Stein Evensen

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Bengt Gustavsson

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Michael Hedenus

6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Gunnar Juliusson

7

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Eva Löfvenberg

8

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Ingerid Nesthus

9

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Bengt Simonsson

10

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Malvin Sjo

11

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Leif Stenke

12

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Jon Magnus Tangen

13

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Ulf Tidefelt

14

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Ann-Mari Udén

15

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Christer Paul

16

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Jan Liliemark

17

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

publication date

1 April 2003

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Leukemia Research

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

323-328

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Multidrug resistance (Mdr1) gene expression in peripheral blasts from patients with acute leukemia only rarely increases during disease progression after combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900181-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0145-2126(02)00181-9

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44280538&oldid=2109107112"